Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rosacea - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H2 2016, provides an overview of the Rosacea (Dermatology) pipeline landscape. Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 7, 3, 1 and 3 respectively for Rosacea. Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology). - The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Rosacea Overview 8 Therapeutics Development 9 Pipeline Products for Rosacea - Overview 9 Rosacea - Therapeutics under Development by Companies 10 Rosacea - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Rosacea - Products under Development by Companies 14 Rosacea - Companies Involved in Therapeutics Development 15 Allergan Plc 15 Amorepacific Corporation 16 Cell Medica Limited 17 Cutanea Life Sciences Inc 18 Foamix Pharmaceuticals Ltd. 19 Hovione FarmaCiencia SA 20 Merz Pharma GmbH & Co. KgaA 21 Promius Pharma, LLC 22 Sol-Gel Technologies Ltd. 23 TWi Pharmaceuticals, Inc. 24 Rosacea - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 AC-701 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 ACUD-1 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 B-244 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 benzoyl peroxide - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 brolucizumab - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 CLS-005 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 DFD-29 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 DMT-200 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 DMT-210 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 DMT-220 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 FMX-103 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 incobotulinumtoxin A - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 itraconazole - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 minocycline - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 omiganan pentahydrochloride - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 oxymetazoline hydrochloride - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 PAC-14028 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Rosacea - Dormant Projects 59 Rosacea - Discontinued Products 61 Rosacea - Product Development Milestones 62 Featured News & Press Releases 62 Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 62 Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea 62 Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea 63 May 24, 2016: Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0% 63 May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea 64 May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 64 May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea 65 Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea 65 Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 66 Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 66 Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 67 Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 68 Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 68 Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 69 Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 70 Appendix 71 Methodology 71 Coverage 71 Secondary Research 71 Primary Research 71 Expert Panel Validation 71 Contact Us 71 Disclaimer 72List of Tables Number of Products under Development for Rosacea, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Rosacea - Pipeline by Allergan Plc, H2 2016 15 Rosacea - Pipeline by Amorepacific Corporation, H2 2016 16 Rosacea - Pipeline by Cell Medica Limited, H2 2016 17 Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2016 18 Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 19 Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2016 20 Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 21 Rosacea - Pipeline by Promius Pharma, LLC, H2 2016 22 Rosacea - Pipeline by Sol-Gel Technologies Ltd., H2 2016 23 Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Rosacea - Dormant Projects, H2 2016 59 Rosacea - Dormant Projects (Contd..1), H2 2016 60 Rosacea - Discontinued Products, H2 2016 61
List of Tables
Number of Products under Development for Rosacea, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Rosacea - Pipeline by Allergan Plc, H2 2016 15 Rosacea - Pipeline by Amorepacific Corporation, H2 2016 16 Rosacea - Pipeline by Cell Medica Limited, H2 2016 17 Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2016 18 Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 19 Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2016 20 Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 21 Rosacea - Pipeline by Promius Pharma, LLC, H2 2016 22 Rosacea - Pipeline by Sol-Gel Technologies Ltd., H2 2016 23 Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Rosacea - Dormant Projects, H2 2016 59 Rosacea - Dormant Projects (Contd..1), H2 2016 60 Rosacea - Discontinued Products, H2 2016 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
